BANGALORE, India / Oct 22, 2025 / Business Wire / Aurigene Oncology Limited , a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held at the Hynes... Read More

HYDERABAD, India / Jul 23, 2025 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q1 FY26 Revenues ₹ 85,452 Mn [Up: 11% YoY; Flat QoQ]... Read More

HYDERABAD, India / May 09, 2025 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25 Revenues ₹ 85,060 Mn ₹ 325,535... Read More

GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA , wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as... Read More

HYDERABAD, India / Mar 13, 2025 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/mL)... Read More

Dr. Reddy’s gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the U.S. and Europe HYDERABAD, India / Feb 06, 2025 / Business Wire / Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that it has... Read More

HYDERABAD, India / Jan 23, 2025 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25 Revenues ₹ 83,586 Mn... Read More

Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) Combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death Launched in India in the same year as its launch in the U.S., making India the... Read More

HYDERABAD, India / Nov 26, 2024 / Business Wire / Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL® Tablets of Merck Sharp and Dohme LLC in the U.S. market. The product will be marketed by Dr. Reddy's. “We are pleased to advance our growth with the launch of a limited-competition... Read More

HYDERABAD, India / Nov 05, 2024 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and half year ended September 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q2FY25 H1FY25 Revenues ₹ 80,162 Mn... Read More

HYDERABAD, India / Oct 25, 2024 / Business Wire / Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science . This marks the third consecutive appearance of Dr. Reddy’s in the list. In 2022, Dr. Reddy’s entered the prestigious list at rank 18. In 2023, the company was placed at number 16. In the latest 2024... Read More

PRINCETON, N.J. / Oct 14, 2024 / Business Wire / Dr. Reddy’s Laboratories Inc. , the U.S. arm of Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopause awareness, benefits, and training, in alignment with Menopause Awareness Month this October. This initiative underscores the company’s... Read More

BENGALURU, India & HYDERABAD, India / Oct 08, 2024 / Business Wire / Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy’s Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India’s first trial for a novel autologous BCMA... Read More

HYDERABAD, India / Oct 02, 2024 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other... Read More

Malaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential partnership is a step towards this cause This potential partnership aims to bring together Kainomyx’s expertise in novel drug discovery, Aurigene’s capability to conduct integrated drug discovery and... Read More

HYDERABAD, India / Jul 29, 2024 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the launch of its proposed biosimilar Rituximab candidate DRL_RI... Read More

HYDERABAD, India / Jul 27, 2024 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q1FY25 Revenues ₹ 76,727 Mn [Up: 14% YoY; 8% QoQ]... Read More

Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC business In recent years, Dr. Reddy’s has increased... Read More

HYDERABAD, India / Jun 03, 2024 / Business Wire / Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and other recombinant... Read More

HYDERABAD, India / May 28, 2024 / Business Wire / Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management... Read More

HYDERABAD, India / May 07, 2024 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY24 FY24 Revenues ₹ 70,830 Mn... Read More

HYDERABAD, India / May 03, 2024 / Business Wire / Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced its launch of Doxycycline Capsules, 40 mg* in the U.S. market, a therapeutic generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA). Dr.... Read More

Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatation India is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a... Read More

Versavo® (bevacizumab) is indicated for the treatment of several types of cancers including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer and metastatic breast cancer Versavo® is the first Dr. Reddy’s biosimilar product to be approved and launched in the UK Previously, Dr. Reddy’s launched... Read More

HYDERABAD, India / Jan 31, 2024 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY24 9MFY24 Revenues Rs. 72,148... Read More

HYDERABAD, India & PRINCETON, N.J. / Jan 03, 2024 / Business Wire / Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced that it has acquired MenoLabs ® business, a leading women’s health and dietary supplement branded portfolio from Amyris, Inc. (“Amyris”) in Amyris’ Chapter 11 sales process. Dr. Reddy’s... Read More

Company also secures ‘Gold Medal’ status from global sustainability ratings agency, EcoVadis In a first for Indian pharma, Dr. Reddy’s is featured in the Dow Jones Sustainability World Index for 2023 Company retains its place in the Dow Jones Sustainability Emerging Markets Index for the 8th year in a row Separately, the global sustainability ratings agency EcoVadis has awarded ‘Gold Medal’ status to Dr. Reddy’s for ranking... Read More

HYDERABAD, India / Oct 27, 2023 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended Sep 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Revenues Rs. 68,802 Mn [Up: 9% YoY; Up: 2% QoQ] Gross... Read More

HYDERABAD, India / Aug 10, 2023 / Business Wire / Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a therapeutic equivalent generic version of KOMBIGLYZE® XR (saxagliptin and metformin hydrochloride extended... Read More

HYDERABAD, India / Jul 26, 2023 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Revenues Rs. 67,384 Mn [Up: 29%* YoY; Up: 7%* QoQ]... Read More

In January 2023, the company had announced the successful completion of the full set of clinical studies of its proposed rituximab biosimilar candidate DRL_RI, with the intention to file in the United States, European Union and other regions Following dossier submission in April 2023, the regulatory agencies have now accepted the dossier for review HYDERABAD, India / Jul 12, 2023 / Business Wire / Dr. Reddy’s Laboratories... Read More

Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Phase I study conducted by Dr. Reddy’s demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity between Dr. Reddy’s proposed... Read More

HYDERABAD, India / May 10, 2023 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023. The information mentioned in this release is on the basis of consolidated... Read More

HYDERABAD, India / Apr 21, 2023 / Business Wire / Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin® (treprostinil) Injection, approved by U. S. Food and Drug Administration (USFDA). Dr. Reddy’s... Read More

HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J. / Feb 27, 2023 / Business Wire / Dr. Reddy's Laboratories SA , wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of... Read More

HYDERABAD, India / Feb 08, 2023 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) announced major back-to-back recognitions in gender equality and sustainability. Dr. Reddy’s has been included in the Bloomberg Gender-Equality Index (GEI) 2023 for a sixth consecutive year , featuring as the only Indian pharma company. The 2023 index... Read More

HYDERABAD, India & PRINCETON, N.J. / Jan 27, 2023 / Business Wire / Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol® (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market, following the... Read More

Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that it has successfully completed the full set of... Read More

Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Phase 1 study conducted by Dr. Reddy’s demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity between Dr. Reddy’s proposed... Read More